Endogenous subclinical hyperthyroidism: who, when and why to treat
Endogenous subclinical hyperthyroidism: who, when and why to treat
复制标题
DOI：
10.1586/eem.11.69
复制
发表时间：
2011-01-01
影响因子：
3.2
通讯作者：
Biondi, Bernadette
中科院分区：
文献类型：
--
作者：
Biondi, Bernadette
亚临床甲状腺功能亢进症被定义为血清甲状腺激素水平在各自的参考范围内，但血清促甲状腺激素刺激激素水平低至不可检测。亚临床甲状腺功能亢进症与重要的心血管危险因素以及对骨代谢和结构的负面影响有关。然而，关于心血管死亡率和骨折风险的结果相互矛盾。亚临床甲亢的治疗和管理存在争议。本文将根据甲状腺功能亢进的病因、患者的年龄、促甲状腺激素抑制的程度以及合并症的存在来讨论治疗这种疾病的必要性。
Subclinical hyperthyroidism is defined as serum thyroid hormone levels within their respective reference ranges in the presence of low-undetectable serum thyrotropin-stimulating hormone levels. Subclinical hyperthyroidism is associated with important cardiovascular risk factors and negative effects on bone metabolism and structure. However, there are conflicting results on cardiovascular mortality and the risk of bone fractures. Treatment and management of subclinical hyperthyroidism is controversial. This article will address the necessity to treat this disorder in relation to the cause of hyperthyroidism, the patient's age, the degree of thyroid-stimulating hormone suppression and the presence of comorbidities.